ET appears to be in a breakout and could see more upside.
I'm going to target the shorter-term trade right now.
Dynavax Technologies, Kala Pharmaceuticals and TherapeuticsMD are three names this biotech investor plans to add exposure to via covered calls.
A trader needs to go where they have comfort, especially if buying shares.
The next move for profit-seeking investors is what I call the 'death short.'
Let look at a 1-2-3 strategy to make money, using Berry and CVS as examples.
Here's a play for MP Materials, a rare-earth materials company, that reports this week.
Plug Power has earnings Thursday. I do not think they are going to go very well.
EBAY is now priced well below my estimated fair value.
This is probably a good place to start accumulating some options.
Federated Hermes is not a home-run kind of stock, but it is a blue-chip name at a very reasonable valuation with great upside potential.
Here's how to play the rail name as we see a shipping shortage yet lots to transport.
I like the chart and elevated implied volatility into the earnings release.
This is a company with a $34 billion market cap. But few have even heard of it.
Shares of Cara Therapeutics, Adverum Biotechnologies and Ardelyx Inc. all took big hits after each company announced unfavorable developments.
Here's why the tech giant stumbled after earnings and what I see as better investments.
I'm going smaller on a trade Thursday with a tight weekly chart that has some explosive upside potential.
Exploding food and grain prices play right into the hands of the fertilizer company.
There's a chance we'll see earnings in May, so traders should keep that in mind.
An interesting options trade on GE went up on Tuesday.
Here's where I would put my stop if I were holding shares of this FinTech.
Let's look at VIAC one month after its fall in late March.
Here's why it's best to focus on a few names that interest you most or influence your portfolio, and not chase every report.
The price action is encouraging me to take a little more risk on beaten down names, and JMIA fits that bill.
There is some negative news out there that is difficult to quantify.
SEIC is likely out of mind for most investors, yet the company is totally 'out of sight.'
Although indices were flat for the week, that is exactly what we need for better technical conditions after the dips.
This name is seeing a lot of call buying.
I'm willing to take a small swing at this one on a call spread.
This simple option strategy, which I continue to use with small-cap biotechs, is one of the easiest and cheapest risk mitigation approaches an individual can take.